Research and Clinical Trials

Title  

Pfizer FRAG-A001-201 (A6301094): A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES

Brief Description  

1. To determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with venous thromboembolism (VTE), and with or without cancer, using anti-Xa (Xa) levels and a population PD analysis methodology 2. To determine the median dose (IU/kg) required to achieve therapeutic anti-Xa levels (0.5 to 1.0 International Units[IU]/mL) based on subject age and weight.

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Ill-Defined Sites

Status  

OPEN

Start Date  

04/05/2017

Principal Investigator  

Hinson, Ashley Rebekah Presar

Contact Name  

Gerri Robinson

For More Information, Contact  Gerri  , Robinson
Phone:  980-442-2355 Fax:    
Email:  gerri.robinson@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204